Compounds > ebelactone a
Page last updated: 2024-11-11

ebelactone a

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

ebelactone A: esterase inhibitor; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6436820
SCHEMBL ID5580619
SCHEMBL ID4367923
MeSH IDM0097151

Synonyms (13)

Synonym
76808-16-7
ebelactone a
nsc 335650
2-oxetanone, 4-(8-hydroxy-1,3,5,7,9-pentamethyl-6-oxo-3-undecenyl)-3-methyl-, (3s-(3-alpha,4-beta(1r*,3e,5s*,7r*,8s*,9s*)))-
3,11-dihydroxy-2,4,6,8,10,12-hexamethyl-9-oxo-6-tetradecenoic 1,3-lactone
ebelactone a microbial, esterase inhibitor
2-oxetanone,4-[(1s,3e,5r,7s,8r,9r)-8-hydroxy-1,3,5,7,9-pentamethyl-6-oxo-3-undecen-1-yl]-3-methyl-,(3s,4s)-
SCHEMBL5580619
SCHEMBL4367923
(-)-ebelactone a
ebelactonea
DTXSID501318085
AKOS040756380
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (15)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (33.33)18.7374
1990's6 (40.00)18.2507
2000's2 (13.33)29.6817
2010's2 (13.33)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 16.77

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index16.77 (24.57)
Research Supply Index2.83 (2.92)
Research Growth Index4.43 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (16.77)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews3 (18.75%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other13 (81.25%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
glycine
[no description available]		3.9820alpha-amino acid;
amino acid zwitterion;
proteinogenic amino acid;
serine family amino acid		EC 2.1.2.1 (glycine hydroxymethyltransferase) inhibitor;
fundamental metabolite;
hepatoprotective agent;
micronutrient;
neurotransmitter;
NMDA receptor agonist;
nutraceutical
hydroxylamine
amino alcohol : An alcohol containing an amino functional group in addition to the alcohol-defining hydroxy group.		1.9810hydroxylaminesalgal metabolite;
bacterial xenobiotic metabolite;
EC 1.1.3.13 (alcohol oxidase) inhibitor;
EC 4.2.1.22 (cystathionine beta-synthase) inhibitor;
EC 4.3.1.10 (serine-sulfate ammonia-lyase) inhibitor;
nitric oxide donor;
nucleophilic reagent
1-anilino-8-naphthalenesulfonate
1-anilino-8-naphthalenesulfonate: RN given refers to parent cpd. 8-anilinonaphthalene-1-sulfonic acid : A naphthalenesulfonic acid that is naphthalene-1-sulfonic acid substituted by a phenylamino group at position 8.		2.6730aminonaphthalene;
naphthalenesulfonic acid		fluorescent probe
iodoacetamide
[no description available]		1.9810
sodium fluoride
[no description available]		1.9710fluoride saltmutagen
isoflurophate
Isoflurophate: A di-isopropyl-fluorophosphate which is an irreversible cholinesterase inhibitor used to investigate the NERVOUS SYSTEM.		2.6830dialkyl phosphate
leucine
Leucine: An essential branched-chain amino acid important for hemoglobin formation.. leucine : A branched-chain amino acid that consists of glycine in which one of the hydrogens attached to the alpha-carbon is substituted by an isobutyl group.		3.9820amino acid zwitterion;
L-alpha-amino acid;
leucine;
proteinogenic amino acid;
pyruvate family amino acid		algal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
plant metabolite;
Saccharomyces cerevisiae metabolite
paraoxon
[no description available]		1.9710aryl dialkyl phosphate;
organophosphate insecticide		EC 3.1.1.7 (acetylcholinesterase) inhibitor;
mouse metabolite
forphenicine
forphenicine: alkaline phosphatase inhibitor from Actinomycetes; structure		3.9820
forphenicinol
[no description available]		3.0610
ubenimex
ubenimex: growth inhibitor		3.9820
fk 156
FK 156: structure given in first source; RN given refers to ((L)(R)-isomer		3.0610
carbodiimides
Carbodiimides: Compounds with the general formula RN=C=NR, where R is a hydrocarbyl group.. methanediimine : A carbodiimide in which both nitrogens are unsubstituted.		1.9810carbodiimide
leucine chloromethyl ketone
leucine chloromethyl ketone: RN given refers to parent cpd without isomeric designation		1.9810
coriolin
coriolin: sesquiterpene antibiotic isolated from Coriolus consors; structure in third source		3.0610
arphamenine b
arphamenine B: from Chromobacterium violaceum; structure given in second source		3.0610
diaminopimelic acid
Diaminopimelic Acid: A diamino derivative of heptanedioic acid with amino groups at C-2 and C-6 and the general formula (COOH)CH(NH2)CH2CH2CH2CH(NH2)(COOH).. LL-2,6-diaminopimelic acid : A 2,6-diaminopimelic acid in which both chiral centres have S configuration. It is a component of bacterial cell wall.		3.06102,6-diaminopimelic acid;
amino acid zwitterion		Escherichia coli metabolite
amastatin
amastatin: structure; inhibits aminopeptidase. amastatin : A tetrapeptide comprising (2S,3R)-3-amino-2-hydroxy-5-methylhexanoyl, L-valyl, L-valyl and L-aspartic acid units joined in sequence		3.9820tetrapeptideEC 3.4.11.* (aminopeptidase) inhibitor;
protease inhibitor
sesquiterpenes
[no description available]		3.0610
ebelactone b
ebelactone B: esterase inhibitor; structure given in first source; see also ebelactone A		4.3260
arphamenine a
arphamenine A: from Chromobacterium violaceum; structure given in second source		3.9820
esterastin
esterastin: inhibitor of esterases; structure		3.9820
ConditionIndicatedRelationship StrengthStudiesTrials
Adenosis of Breast
[description not available]		01.9710
Fibrocystic Breast Disease
A common and benign breast disease characterized by varying degree of fibrocystic changes in the breast tissue. There are three major patterns of morphological changes, including FIBROSIS, formation of CYSTS, and proliferation of glandular tissue (adenosis). The fibrocystic breast has a dense irregular, lumpy, bumpy consistency.		01.9710
Bacterial Disease
[description not available]		01.9710
Amnionitis
[description not available]		01.9710
Bacterial Infections
Infections by bacteria, general or unspecified.		01.9710
Chorioamnionitis
INFLAMMATION of the placental membranes (CHORION; AMNION) and connected tissues such as fetal BLOOD VESSELS and UMBILICAL CORD. It is often associated with intrauterine ascending infections during PREGNANCY.		01.9710
Pregnancy
The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.		01.9710
Sensitivity and Specificity
Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)		01.9710
Delayed Hypersensitivity
[description not available]		02.8810
Leukemia L 1210
[description not available]		02.8810
Infection
[description not available]		02.8810
Experimental Neoplasms
[description not available]		02.8810
Infections
Invasion of the host organism by microorganisms or their toxins or by parasites that can cause pathological conditions or diseases.		02.8810